Journal of Hypertension: Open Access

Salih Çetiner

Publications

• Research Article
  A Novel BioTarget in Treatment of Heart Failure: Changes in Serum Galectin-3 Levels after Spironolactone Therapy
  Author(s): Onur Sinan Deveci, Aziz Inan Çelik, Müslüm Firat Ikikardes, Çaglar Emre Çagliyan, Çaglar Özmen, Ali Deniz, Rabia Eker Akilli, Filiz Kibar, Salih Çetiner, Mesut Demir, Mehmet Kanadasi and Mustafa DemirtasOnur Sinan Deveci, Aziz Inan Çelik, Müslüm Firat Ikikardes, Çaglar Emre Çagliyan, Çaglar Özmen, Ali Deniz, Rabia Eker Akilli, Filiz Kibar, Salih Çetiner, Mesut Demir, Mehmet Kanadasi and Mustafa Demirtas
  
  ObjectÃ?±ve: It has been aimed to investigate the Galectin-3 (GAL-3) levels and clinical responses after addition of spironolactone as a mineralocorticoid receptor antagonist (MRA) to the current treatment in patients with heart failure with low ejection fraction who received no aldosterone antagonist therapy previously. PatÃ?±ents and methods: The study included 112 patients with Heart Failure (HF) who showed left ventricular Ejection Fraction (EF) of 35% or below, New York Heart Association (NYHA) Class II-IV symptoms and did not receive MRAs in their current treatment. Serum Gal-3 levels, serum BNP level, 6-minute walk test and class level of NYHA were examined before and 6 months after treatment of spironolactone in all patients. Results: Mortality developed in 10 of 112 patients. Baseline and 6th month .. Read More»
  DOI: 10.4172/2167-1095.1000195

  Abstract PDF